Camurus AB/Skr CAMX
1D1W1MYTD1Y5YMAX
Capital at risk
About Camurus AB
Camurus AB is a biopharmaceutical company headquartered in Lund, Sweden, specializing in the development of innovative pharmaceuticals for the treatment of serious and chronic diseases. The company's core offerings focus on proprietary drug delivery technologies, including FluidCrystal® technology, which enhances the therapeutic benefits and delivery of active ingredients. Camurus concentrates its efforts on areas such as addiction treatment, pain management, and oncology, aiming to improve patient outcomes through advanced formulations. The company operates in several international markets, leveraging strategic partnerships and a focused product pipeline to maintain its position within the biopharmaceutical industry. Its operations are characterized by a strong emphasis on research and development to sustain and expand its portfolio.
- Ticker
- Skr CAMX
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 316
- Headquarters
- Lund, Sweden
- Website
- www.camurus.com
Camurus AB Metrics
BasicAdvanced
kr 34B
51.03
kr 11.31
0.51
-
Price and volume
Market cap
kr 34B
Beta
0.51
52-week high
kr 714.50
52-week low
kr 430.80
Average daily volume
76K
Financial strength
Current ratio
10.005
Quick ratio
9.346
Long term debt to equity
0.019
Total debt to equity
0.023
Interest coverage (TTM)
140.93%
Profitability
EBITDA (TTM)
822.984
Gross margin (TTM)
93.07%
Net profit margin (TTM)
29.92%
Operating margin (TTM)
35.96%
Effective tax rate (TTM)
21.66%
Revenue per employee (TTM)
kr 7,170,000
Management effectiveness
Return on assets (TTM)
10.47%
Return on equity (TTM)
15.86%
Valuation
Price to earnings (TTM)
51.029
Price to revenue (TTM)
15.177
Price to book
7.34
Price to tangible book (TTM)
7.34
Price to free cash flow (TTM)
52.545
Free cash flow yield (TTM)
1.90%
Free cash flow per share (TTM)
10.981
Growth
Revenue change (TTM)
0.01%
Earnings per share change (TTM)
-6.16%
3-year revenue growth (CAGR)
15.59%
10-year revenue growth (CAGR)
34.20%
3-year earnings per share growth (CAGR)
16.80%
10-year earnings per share growth (CAGR)
14.55%
Bulls say / Bears say
Product sales increased 13% year-on-year to MSEK 528, driven by renewed Buvidal growth and a 42% rise in Brixadi royalty revenue, underscoring strong commercial momentum (Camurus Q2 Report)
Eli Lilly’s exercise of its option to include amylin receptor agonists under the FluidCrystal® collaboration validates the platform and could deliver up to USD 870 million in milestone payments plus royalties, enhancing Camurus’ long-term revenue potential (Camurus Lilly Collaboration)
The FDA’s acceptance of the NDA resubmission for CAM2029 with a PDUFA target date of December 18, 2026 reduces regulatory uncertainty and preserves the timeline for U.S. market entry of Oclaiz™ (Camurus NDA Resubmission Accepted)
The FDA issued a Complete Response Letter for the CAM2029 NDA due to cGMP inspection observations at a third-party manufacturer, delaying approval pending remediation and a facility reinspection, which could push the U.S. launch into late 2026 (Camurus Regulatory Update)
Milestone payments in Q2 plunged to MSEK 46 from MSEK 115 in the prior quarter, highlighting the volatility of non-recurring revenue streams (Camurus Q2 Report)
Operating profit for H1 2026 fell 13% to MSEK 461 from MSEK 531, reflecting increased R&D and SG&A spending that compressed margins despite revenue growth (Camurus Q2 Report)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Upcoming events
No upcoming events
Funds containing Camurus AB
AllEURGBPUSD
Fund name | Fund size | Skr CAMX weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.16% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.16% |
Amundi STOXX Europe 600 ESG€C6E | €735M | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.